KIT and melanoma: In humans, the use of tyrosine kinase inhibitors (TKIs) has a better effect on patients affected by tumors bearing SNPs in KIT [8,13,27,40], particularly in GIST [41], some types of melanomas [11,20,40], chronic myeloid leukemia [42], and systemic mastocytosis [43].